Porcine circovirus 2 (PCV2) infections are related to a number of syndromes and clinical manifestations, generally known as Porcine circovirus-associated diseases, which are related to losses in the swine industry. There are commercially available vaccines and new vaccines being tested, however, persistency of the PCV2 as an important pig pathogen, and the growing number of affected farms in different countries have suggested that there is room for vaccine improvement. In this study, we describe the construction and testing of a recombinant live vaccine based on a modified Vaccinia virus Ankara (MVA) vector expressing the PCV2b capsid protein (CAP). Using a two-dose homologous vaccination regimen, in mice, we demonstrated that the vaccine induced high titers of anti-PCV2 antibodies. The vaccine is stable upon lyophilization, and, together with the good immunogenicity potential observed, the results support further evaluation of the MVA-CAP vaccine in the target species.

中文翻译：

---

简短交流：基于安卡拉的改良牛痘病毒猪圆环病毒 2 疫苗在临床前模型中引发强烈的抗体反应

猪圆环病毒 2 (PCV2) 感染与许多综合征和临床表现有关，通常称为猪圆环病毒相关疾病，与养猪业的损失有关。有市售疫苗和正在测试的新疫苗，然而，PCV2 作为一种重要的猪病原体的持久性以及不同国家越来越多的受影响农场表明疫苗仍有改进的空间。在这项研究中，我们描述了基于表达 PCV2b 衣壳蛋白 (CAP) 的改良痘苗病毒安卡拉 (MVA) 载体的重组活疫苗的构建和测试。在小鼠中使用两剂同源疫苗接种方案，我们证明疫苗诱导了高滴度的抗 PCV2 抗体。该疫苗在冻干后是稳定的，并且，